Table 1 Targeted therapy for hemophagocytic lymphohistiocytosis (HLH) in ongoing clinical trials
Target | NCT Number | HLH type | Interventions | Phase | No. Patient | Start Date | Study status |
|---|---|---|---|---|---|---|---|
IFN-γ | NCT06038422 | R/R HLH | GTP | 3 | 15 | 2023/9/15 | Not yet recruiting |
IFN-γ | NCT05744063 | Primary HLH | Emapalumab | 4 | 13 | 2023/2/3 | Active not recruiting |
IFN-γ | NCT05001737 | MAS | Emapalumab | 3 | 41 | 2021/12/15 | Recruiting |
JAK1/2 | NCT06244862 | Severe HLH | Ruxolitinib | 2 | 42 | 2024/2/1 | Not yet recruiting |
JAK1/2 | NCT06160791 | HLH | Ruxolitinib + ED | 2 | 36 | 2024/2/1 | Not yet recruiting |
JAK1/2 | NCT05762640 | Primary HLH | Ruxolitinib | 2 | 20 | 2024/3/1 | Not yet recruiting |
JAK1/2 | NCT05491304 | Pediatric HLH | Ruxolitinib + ED | 4 | 400 | 2022/9/1 | Recruiting |
JAK1/2 | NCT05137496 | MAS | Ruxolitinib + methylprednisolone | 3 | 40 | 2022/6/1 | Not yet recruiting |
JAK1/2 | NCT04999878 | Lymphoma-associated HLH | RUE-DDGP | 4 | 30 | 2021/5/30 | Recruiting |
JAK1/2 | NCT04551131 | HLH | Ruxolitinib + ED | 1/2 | 62 | 2021/7/13 | Recruiting |
JAK1/2 | NCT04120090 | R/R HLH | ruxolitinib | 3 | 80 | 2019/7/1 | Unknown |
JAK1/2 | NCT03795909 | R/R HLH | Ruxolitinib + Dex | 1/2 | 50 | 2017/3/1 | Unknown |
JAK1 | NCT05063110 | Non-severe HLH | Itacitinib | 2 | 63 | 2022/5/1 | Recruiting |
JAK2 | NCT04326348 | HLH | TQ05105 | 1 | 40 | 2020/7/17 | Unknown |
IL-6 | NCT02007239 | HLH | Tocilizumab | 2 | NA | 2013/12/1 | Withdrawn |
IL-1 | NCT02780583 | MAS | Anakinra | 1 | 40 | 2016/5/15 | Active not recruiting |
IL-18 | NCT03512314 | NLRC4-MAS, XIAP Deficiency | Tadekinig alfa (IL-18BP) | 3 | 10 | 2018/1/24 | Active not recruiting |
CD52 | NCT01821781 | HLH | Conditioning regimen before HSCT: Flu + Mel + Alem + thiotepa | 2 | 20 | 2013/3/1 | Recruiting |
CD20 | NCT05384743 | EBV-HLH | Rituximab | 3 | 30 | 2022/2/1 | Unknown |
CD20 | NCT05258136 | EBV-HLH | CD20 monoclonal antibody | NA | 20 | 2021/6/1 | Enrolling by invitation |
PD-1 | NCT05008666 | ENKTL-HLH | Sintilimab + chidamide + azacitidine | 2 | 37 | 2021/12/1 | Unknown |
PD-1 | NCT05775705 | HLH | PD-1 antibody + L-DEP | 3 | 25 | 2023/8/1 | Not yet recruiting |
PD-1 | NCT05315336 | HLH | PD-1 antibody + L-DEP | 3 | 50 | 2022/6/1 | Not yet recruiting |
PD-1 | NCT05164978 | HLH | PD-1 antibody + DEP | NA | 20 | 2021/5/1 | Unknown |
PD-1 | NCT05039580 | HLH | PD-1 antibody + L-DEP | 4 | 36 | 2021/5/15 | Unknown |
PD-1 | NCT04084626 | HLH | PD-1 antibody + lenalidomide | 3 | 40 | 2019/9/15 | Unknown |
PD-1 | NCT04944511 | HLH after allo-HSCT | Toripalimab | NA | 20 | 2021/7/1 | Unknown |
PD-1 | NCT04690036 | EBV-HLH after transplantation | Toripalimab | 1 | 20 | 2021/7/1 | Unknown |
IL-18 + IL-1β | NCT04641442 | NLRC4-GOF, XIAP Deficiency, CDC42 Mutations | MAS825 (anti-IL-1β/IL-18) | 2 | 18 | 2020/12/18 | Recruiting |